| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 170 | 2025 | 716 | 23.700 |
Why?
|
| Cardiovascular Diseases | 181 | 2025 | 1877 | 20.840 |
Why?
|
| Atherosclerosis | 165 | 2025 | 835 | 19.400 |
Why?
|
| Cholesterol, LDL | 183 | 2025 | 560 | 18.660 |
Why?
|
| Anticholesteremic Agents | 103 | 2024 | 233 | 16.690 |
Why?
|
| Hypercholesterolemia | 76 | 2024 | 226 | 16.530 |
Why?
|
| Troponin T | 74 | 2024 | 245 | 10.600 |
Why?
|
| Coronary Disease | 85 | 2024 | 637 | 9.120 |
Why?
|
| Hypolipidemic Agents | 51 | 2024 | 176 | 8.610 |
Why?
|
| Triglycerides | 90 | 2025 | 562 | 8.310 |
Why?
|
| Hypertriglyceridemia | 43 | 2025 | 100 | 8.180 |
Why?
|
| Dyslipidemias | 42 | 2025 | 228 | 7.780 |
Why?
|
| Lipoprotein(a) | 36 | 2024 | 114 | 7.670 |
Why?
|
| Natriuretic Peptide, Brain | 50 | 2024 | 274 | 7.450 |
Why?
|
| Biomarkers | 181 | 2025 | 2953 | 7.210 |
Why?
|
| Coronary Artery Disease | 80 | 2024 | 750 | 7.140 |
Why?
|
| Eicosapentaenoic Acid | 38 | 2025 | 79 | 6.970 |
Why?
|
| Cholesterol, HDL | 82 | 2024 | 350 | 6.960 |
Why?
|
| Fatty Acids | 22 | 2024 | 338 | 6.020 |
Why?
|
| Heart Failure | 64 | 2024 | 2131 | 5.970 |
Why?
|
| Peptide Fragments | 46 | 2024 | 747 | 5.930 |
Why?
|
| Ezetimibe | 43 | 2023 | 95 | 5.830 |
Why?
|
| Hyperlipoproteinemia Type II | 29 | 2024 | 84 | 5.800 |
Why?
|
| Cholesterol | 57 | 2023 | 528 | 5.770 |
Why?
|
| Dicarboxylic Acids | 17 | 2024 | 34 | 5.600 |
Why?
|
| Middle Aged | 448 | 2025 | 26089 | 5.480 |
Why?
|
| Risk Factors | 264 | 2025 | 10035 | 5.460 |
Why?
|
| Hyperlipidemias | 30 | 2025 | 174 | 5.430 |
Why?
|
| C-Reactive Protein | 64 | 2024 | 406 | 5.230 |
Why?
|
| Lipids | 60 | 2023 | 513 | 5.160 |
Why?
|
| Risk Assessment | 109 | 2025 | 3336 | 4.970 |
Why?
|
| Stroke | 42 | 2024 | 958 | 4.900 |
Why?
|
| Aged | 315 | 2025 | 19196 | 4.790 |
Why?
|
| Humans | 744 | 2025 | 123265 | 4.670 |
Why?
|
| Myocardial Infarction | 39 | 2025 | 1003 | 4.590 |
Why?
|
| Double-Blind Method | 96 | 2025 | 1601 | 4.310 |
Why?
|
| Male | 526 | 2025 | 60335 | 4.300 |
Why?
|
| Cardiology | 25 | 2023 | 474 | 4.240 |
Why?
|
| Lipoproteins | 26 | 2022 | 177 | 4.170 |
Why?
|
| Female | 506 | 2025 | 65619 | 3.930 |
Why?
|
| Fluorobenzenes | 25 | 2014 | 38 | 3.830 |
Why?
|
| Obesity | 40 | 2024 | 2235 | 3.740 |
Why?
|
| Metabolic Syndrome | 28 | 2023 | 329 | 3.620 |
Why?
|
| Apolipoprotein C-III | 14 | 2025 | 37 | 3.610 |
Why?
|
| Simvastatin | 30 | 2018 | 75 | 3.590 |
Why?
|
| Plaque, Atherosclerotic | 25 | 2023 | 120 | 3.480 |
Why?
|
| Inflammation | 37 | 2024 | 1405 | 3.470 |
Why?
|
| Atrial Fibrillation | 16 | 2024 | 626 | 3.380 |
Why?
|
| Proprotein Convertase 9 | 22 | 2024 | 69 | 3.370 |
Why?
|
| Sulfonamides | 25 | 2014 | 259 | 3.360 |
Why?
|
| United States | 167 | 2024 | 10654 | 3.130 |
Why?
|
| Pyrimidines | 25 | 2014 | 373 | 3.110 |
Why?
|
| Diabetes Mellitus | 40 | 2024 | 850 | 3.080 |
Why?
|
| Drug Therapy, Combination | 53 | 2023 | 1142 | 3.010 |
Why?
|
| Heptanoic Acids | 32 | 2014 | 77 | 2.880 |
Why?
|
| Brain Ischemia | 13 | 2023 | 258 | 2.870 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2024 | 1237 | 2.830 |
Why?
|
| Prospective Studies | 121 | 2024 | 6030 | 2.800 |
Why?
|
| Carotid Artery Diseases | 18 | 2015 | 147 | 2.790 |
Why?
|
| Apolipoproteins B | 27 | 2024 | 131 | 2.750 |
Why?
|
| Pyrroles | 33 | 2015 | 178 | 2.750 |
Why?
|
| Acute Coronary Syndrome | 16 | 2024 | 203 | 2.720 |
Why?
|
| Peripheral Arterial Disease | 22 | 2023 | 275 | 2.690 |
Why?
|
| Incidence | 85 | 2025 | 3054 | 2.670 |
Why?
|
| Azetidines | 24 | 2014 | 55 | 2.630 |
Why?
|
| Troponin I | 10 | 2024 | 96 | 2.490 |
Why?
|
| American Heart Association | 17 | 2021 | 295 | 2.480 |
Why?
|
| Fenofibrate | 12 | 2014 | 58 | 2.480 |
Why?
|
| Monocytes | 15 | 2025 | 346 | 2.450 |
Why?
|
| Fatty Acids, Omega-3 | 11 | 2023 | 69 | 2.410 |
Why?
|
| Treatment Outcome | 116 | 2025 | 12170 | 2.370 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 20 | 2022 | 87 | 2.290 |
Why?
|
| Proprotein Convertases | 11 | 2023 | 22 | 2.140 |
Why?
|
| Platelet Aggregation Inhibitors | 18 | 2021 | 257 | 2.120 |
Why?
|
| Serine Proteinase Inhibitors | 5 | 2019 | 35 | 2.110 |
Why?
|
| Practice Guidelines as Topic | 32 | 2021 | 1253 | 2.060 |
Why?
|
| Time Factors | 75 | 2024 | 6223 | 2.020 |
Why?
|
| Indoles | 22 | 2011 | 181 | 2.000 |
Why?
|
| Follow-Up Studies | 86 | 2024 | 5056 | 1.970 |
Why?
|
| Adult | 163 | 2025 | 29100 | 1.940 |
Why?
|
| Prognosis | 63 | 2025 | 4511 | 1.930 |
Why?
|
| Antibodies, Monoclonal | 21 | 2024 | 1010 | 1.920 |
Why?
|
| Hypertension | 32 | 2024 | 1284 | 1.800 |
Why?
|
| Polymorphism, Single Nucleotide | 35 | 2024 | 2586 | 1.790 |
Why?
|
| Niacin | 15 | 2016 | 57 | 1.790 |
Why?
|
| Coronary Artery Bypass | 15 | 2021 | 490 | 1.730 |
Why?
|
| Blood Pressure | 30 | 2024 | 1326 | 1.730 |
Why?
|
| Adipose Tissue | 11 | 2020 | 465 | 1.730 |
Why?
|
| Insulin Resistance | 16 | 2021 | 644 | 1.610 |
Why?
|
| Cholesterol Ester Transfer Proteins | 13 | 2024 | 37 | 1.600 |
Why?
|
| Lipid Metabolism | 8 | 2024 | 349 | 1.590 |
Why?
|
| Myocardial Ischemia | 17 | 2021 | 332 | 1.590 |
Why?
|
| Oxazolidinones | 4 | 2017 | 32 | 1.580 |
Why?
|
| Dose-Response Relationship, Drug | 31 | 2024 | 1689 | 1.580 |
Why?
|
| Aged, 80 and over | 56 | 2024 | 6392 | 1.570 |
Why?
|
| Galectin 3 | 8 | 2024 | 31 | 1.570 |
Why?
|
| Cohort Studies | 61 | 2024 | 4701 | 1.470 |
Why?
|
| Inflammation Mediators | 13 | 2020 | 233 | 1.450 |
Why?
|
| Carotid Intima-Media Thickness | 15 | 2023 | 73 | 1.440 |
Why?
|
| Lipoproteins, LDL | 18 | 2021 | 116 | 1.420 |
Why?
|
| Rosuvastatin Calcium | 28 | 2021 | 41 | 1.410 |
Why?
|
| Hospitalization | 14 | 2021 | 1737 | 1.400 |
Why?
|
| Proportional Hazards Models | 39 | 2022 | 1304 | 1.390 |
Why?
|
| Primary Prevention | 14 | 2023 | 165 | 1.380 |
Why?
|
| Weight Loss | 15 | 2017 | 481 | 1.360 |
Why?
|
| RNA, Small Interfering | 5 | 2024 | 667 | 1.340 |
Why?
|
| Apolipoprotein A-I | 17 | 2018 | 79 | 1.340 |
Why?
|
| Lipoproteins, HDL | 14 | 2024 | 96 | 1.340 |
Why?
|
| Fatty Acids, Monounsaturated | 18 | 2009 | 49 | 1.320 |
Why?
|
| CD11c Antigen | 8 | 2021 | 35 | 1.320 |
Why?
|
| RNAi Therapeutics | 3 | 2024 | 17 | 1.310 |
Why?
|
| Serine Endopeptidases | 11 | 2023 | 175 | 1.290 |
Why?
|
| Vascular Calcification | 7 | 2024 | 54 | 1.290 |
Why?
|
| Life Style | 12 | 2024 | 406 | 1.270 |
Why?
|
| Heart Diseases | 8 | 2022 | 481 | 1.260 |
Why?
|
| Antibodies, Monoclonal, Humanized | 16 | 2023 | 489 | 1.190 |
Why?
|
| Risk Reduction Behavior | 12 | 2021 | 139 | 1.170 |
Why?
|
| Muscle, Skeletal | 8 | 2023 | 941 | 1.150 |
Why?
|
| Secondary Prevention | 9 | 2022 | 212 | 1.150 |
Why?
|
| Pancreatitis | 3 | 2024 | 129 | 1.140 |
Why?
|
| Carotid Artery, Common | 4 | 2011 | 73 | 1.130 |
Why?
|
| Muscular Diseases | 5 | 2022 | 102 | 1.110 |
Why?
|
| Exercise | 12 | 2022 | 814 | 1.110 |
Why?
|
| Predictive Value of Tests | 32 | 2024 | 2114 | 1.100 |
Why?
|
| Sulfhydryl Compounds | 9 | 2020 | 53 | 1.090 |
Why?
|
| Apolipoproteins A | 6 | 2014 | 46 | 1.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 21 | 2010 | 133 | 1.040 |
Why?
|
| Prevalence | 30 | 2024 | 2409 | 1.030 |
Why?
|
| Diabetes Complications | 6 | 2020 | 196 | 1.030 |
Why?
|
| Polymorphism, Genetic | 17 | 2019 | 807 | 1.030 |
Why?
|
| Foam Cells | 3 | 2025 | 20 | 1.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 387 | 1.030 |
Why?
|
| Registries | 20 | 2024 | 1398 | 1.000 |
Why?
|
| Myositis | 3 | 2017 | 51 | 0.990 |
Why?
|
| Myocardial Revascularization | 8 | 2024 | 96 | 0.990 |
Why?
|
| Apolipoproteins E | 15 | 2021 | 189 | 0.980 |
Why?
|
| Galectins | 5 | 2022 | 18 | 0.970 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 160 | 0.960 |
Why?
|
| Body Mass Index | 26 | 2024 | 1553 | 0.960 |
Why?
|
| Renal Insufficiency, Chronic | 12 | 2022 | 716 | 0.960 |
Why?
|
| Carotid Arteries | 9 | 2015 | 151 | 0.950 |
Why?
|
| Healthcare Disparities | 6 | 2021 | 417 | 0.950 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 10 | 2010 | 63 | 0.940 |
Why?
|
| Dioxygenases | 2 | 2024 | 46 | 0.940 |
Why?
|
| Receptors, LDL | 9 | 2025 | 89 | 0.930 |
Why?
|
| Cross-Sectional Studies | 42 | 2024 | 3384 | 0.930 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2020 | 714 | 0.910 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 17 | 0.900 |
Why?
|
| Chromosomes, Human, Pair 9 | 5 | 2017 | 106 | 0.890 |
Why?
|
| Residence Characteristics | 12 | 2021 | 268 | 0.880 |
Why?
|
| Myocardium | 21 | 2019 | 986 | 0.880 |
Why?
|
| Up-Regulation | 13 | 2020 | 862 | 0.870 |
Why?
|
| Intra-Abdominal Fat | 2 | 2017 | 51 | 0.870 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2024 | 547 | 0.870 |
Why?
|
| Genome-Wide Association Study | 20 | 2019 | 1637 | 0.860 |
Why?
|
| Ageism | 1 | 2023 | 4 | 0.860 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2023 | 3549 | 0.850 |
Why?
|
| Medication Adherence | 10 | 2021 | 389 | 0.840 |
Why?
|
| Societies, Medical | 6 | 2021 | 678 | 0.810 |
Why?
|
| Carotid Artery, Internal | 3 | 2015 | 68 | 0.800 |
Why?
|
| Coronary Vessels | 15 | 2024 | 527 | 0.800 |
Why?
|
| Interleukin-6 | 13 | 2024 | 395 | 0.790 |
Why?
|
| Animals | 76 | 2025 | 33859 | 0.790 |
Why?
|
| Repressor Proteins | 2 | 2024 | 816 | 0.780 |
Why?
|
| Oligonucleotides | 3 | 2024 | 88 | 0.770 |
Why?
|
| Drug Costs | 2 | 2019 | 60 | 0.770 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2024 | 1080 | 0.760 |
Why?
|
| Football | 5 | 2014 | 30 | 0.760 |
Why?
|
| Macrophage-1 Antigen | 7 | 2014 | 26 | 0.760 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 473 | 0.760 |
Why?
|
| Fish Oils | 2 | 2021 | 83 | 0.760 |
Why?
|
| Dietary Supplements | 4 | 2021 | 475 | 0.750 |
Why?
|
| Cardiomyopathies | 7 | 2019 | 478 | 0.750 |
Why?
|
| Drug Tolerance | 2 | 2021 | 40 | 0.750 |
Why?
|
| Odds Ratio | 20 | 2021 | 1245 | 0.740 |
Why?
|
| Linear Models | 13 | 2017 | 669 | 0.730 |
Why?
|
| Eligibility Determination | 2 | 2019 | 37 | 0.710 |
Why?
|
| DNA-Binding Proteins | 4 | 2024 | 2054 | 0.710 |
Why?
|
| Hypoglycemic Agents | 5 | 2022 | 429 | 0.710 |
Why?
|
| Calcinosis | 7 | 2024 | 170 | 0.710 |
Why?
|
| Lipoprotein Lipase | 10 | 2023 | 54 | 0.700 |
Why?
|
| Young Adult | 31 | 2024 | 8867 | 0.700 |
Why?
|
| Postprandial Period | 4 | 2016 | 77 | 0.700 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 3 | 2019 | 8 | 0.700 |
Why?
|
| Genetic Variation | 10 | 2017 | 1479 | 0.690 |
Why?
|
| Blood Glucose | 21 | 2021 | 1123 | 0.690 |
Why?
|
| Longitudinal Studies | 18 | 2023 | 1315 | 0.690 |
Why?
|
| Risk | 15 | 2019 | 747 | 0.690 |
Why?
|
| Mice, Inbred C57BL | 28 | 2025 | 4369 | 0.690 |
Why?
|
| Cause of Death | 8 | 2024 | 463 | 0.680 |
Why?
|
| United States Department of Veterans Affairs | 10 | 2021 | 659 | 0.680 |
Why?
|
| Disease Progression | 27 | 2024 | 2030 | 0.670 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 61 | 0.670 |
Why?
|
| Cognition Disorders | 2 | 2021 | 555 | 0.670 |
Why?
|
| Lipoproteins, VLDL | 4 | 2018 | 58 | 0.670 |
Why?
|
| Mortality | 5 | 2020 | 228 | 0.670 |
Why?
|
| Population Surveillance | 6 | 2021 | 383 | 0.670 |
Why?
|
| Retirement | 4 | 2014 | 18 | 0.660 |
Why?
|
| Smoking | 13 | 2024 | 1031 | 0.660 |
Why?
|
| Clinical Trials as Topic | 13 | 2020 | 1084 | 0.650 |
Why?
|
| Comorbidity | 16 | 2024 | 1497 | 0.650 |
Why?
|
| Chemokine CCL5 | 3 | 2013 | 54 | 0.650 |
Why?
|
| Age Factors | 21 | 2025 | 2811 | 0.650 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 25 | 0.650 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 286 | 0.640 |
Why?
|
| Drug Administration Schedule | 13 | 2019 | 726 | 0.640 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2017 | 97 | 0.630 |
Why?
|
| Guideline Adherence | 13 | 2019 | 373 | 0.630 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 130 | 0.630 |
Why?
|
| Carotid Stenosis | 4 | 2021 | 133 | 0.630 |
Why?
|
| Endothelium, Vascular | 11 | 2021 | 516 | 0.620 |
Why?
|
| Chemokine CCL2 | 7 | 2019 | 114 | 0.620 |
Why?
|
| CD18 Antigens | 8 | 2017 | 49 | 0.610 |
Why?
|
| Genetic Testing | 6 | 2022 | 997 | 0.610 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2022 | 106 | 0.610 |
Why?
|
| Preventive Health Services | 2 | 2021 | 58 | 0.610 |
Why?
|
| Disease Management | 5 | 2019 | 515 | 0.610 |
Why?
|
| Mice, Knockout | 24 | 2025 | 3727 | 0.610 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2021 | 827 | 0.610 |
Why?
|
| Heart Transplantation | 13 | 2005 | 854 | 0.610 |
Why?
|
| Vitamin D | 2 | 2017 | 159 | 0.600 |
Why?
|
| Veterans Health | 6 | 2020 | 174 | 0.600 |
Why?
|
| Sex Factors | 22 | 2021 | 1265 | 0.600 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 644 | 0.600 |
Why?
|
| Ischemia | 6 | 2022 | 344 | 0.600 |
Why?
|
| Pravastatin | 5 | 2012 | 23 | 0.600 |
Why?
|
| Cytokines | 5 | 2020 | 1282 | 0.600 |
Why?
|
| Logistic Models | 19 | 2017 | 1801 | 0.590 |
Why?
|
| Mice | 50 | 2025 | 17562 | 0.590 |
Why?
|
| Aspirin | 8 | 2020 | 220 | 0.590 |
Why?
|
| Protein Precursors | 5 | 2021 | 149 | 0.590 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 114 | 0.590 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 1693 | 0.580 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 89 | 0.580 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 6 | 2008 | 26 | 0.570 |
Why?
|
| Energy Metabolism | 2 | 2024 | 774 | 0.570 |
Why?
|
| Cell Adhesion Molecules | 12 | 2003 | 224 | 0.570 |
Why?
|
| Renal Insufficiency | 3 | 2011 | 234 | 0.570 |
Why?
|
| Severity of Illness Index | 25 | 2021 | 2854 | 0.560 |
Why?
|
| Dementia | 2 | 2024 | 448 | 0.560 |
Why?
|
| Genotype | 32 | 2023 | 2538 | 0.560 |
Why?
|
| Tunica Intima | 7 | 2014 | 59 | 0.560 |
Why?
|
| Neutrophils | 13 | 2017 | 372 | 0.550 |
Why?
|
| Antihypertensive Agents | 8 | 2024 | 396 | 0.550 |
Why?
|
| Myocardial Reperfusion Injury | 9 | 2019 | 145 | 0.540 |
Why?
|
| Apolipoproteins | 9 | 2023 | 68 | 0.540 |
Why?
|
| Adiponectin | 5 | 2013 | 109 | 0.530 |
Why?
|
| Ultrasonography, Interventional | 9 | 2018 | 196 | 0.530 |
Why?
|
| Coronary Angiography | 14 | 2024 | 421 | 0.520 |
Why?
|
| Drug Prescriptions | 7 | 2020 | 219 | 0.520 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2015 | 195 | 0.520 |
Why?
|
| Esters | 10 | 2020 | 29 | 0.520 |
Why?
|
| Global Health | 4 | 2024 | 546 | 0.520 |
Why?
|
| Phenotype | 17 | 2024 | 4228 | 0.520 |
Why?
|
| Genetic Loci | 7 | 2019 | 332 | 0.510 |
Why?
|
| Veterans | 8 | 2023 | 1737 | 0.510 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2013 | 429 | 0.510 |
Why?
|
| Genetic Markers | 4 | 2015 | 606 | 0.510 |
Why?
|
| Phospholipases A | 3 | 2006 | 39 | 0.510 |
Why?
|
| Vascular Stiffness | 4 | 2021 | 75 | 0.510 |
Why?
|
| Prediabetic State | 5 | 2021 | 57 | 0.510 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 71 | 0.500 |
Why?
|
| Calcium | 9 | 2022 | 1098 | 0.500 |
Why?
|
| Down-Regulation | 7 | 2021 | 697 | 0.500 |
Why?
|
| Clinical Decision-Making | 5 | 2022 | 265 | 0.500 |
Why?
|
| Troponin | 5 | 2024 | 71 | 0.490 |
Why?
|
| Cell Adhesion | 12 | 2010 | 318 | 0.490 |
Why?
|
| Glomerular Filtration Rate | 12 | 2021 | 482 | 0.490 |
Why?
|
| Patient Selection | 5 | 2019 | 683 | 0.480 |
Why?
|
| Enzyme Inhibitors | 4 | 2017 | 576 | 0.480 |
Why?
|
| Heterozygote | 5 | 2021 | 678 | 0.480 |
Why?
|
| Consensus | 7 | 2024 | 610 | 0.480 |
Why?
|
| Amides | 9 | 2020 | 83 | 0.480 |
Why?
|
| Dietary Fats | 7 | 2015 | 296 | 0.480 |
Why?
|
| Endothelial Cells | 4 | 2021 | 529 | 0.470 |
Why?
|
| Receptors, Immunologic | 5 | 2014 | 109 | 0.470 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 84 | 0.460 |
Why?
|
| Interleukins | 2 | 2014 | 118 | 0.460 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 496 | 0.460 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2024 | 38 | 0.460 |
Why?
|
| Leg | 5 | 2023 | 155 | 0.460 |
Why?
|
| Blood Proteins | 6 | 2022 | 116 | 0.450 |
Why?
|
| Physicians | 5 | 2023 | 581 | 0.450 |
Why?
|
| Alcohol Drinking | 7 | 2019 | 337 | 0.450 |
Why?
|
| Goals | 2 | 2011 | 128 | 0.450 |
Why?
|
| Hyperlipoproteinemia Type I | 2 | 2024 | 5 | 0.450 |
Why?
|
| Texas | 14 | 2024 | 3558 | 0.450 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2024 | 3079 | 0.440 |
Why?
|
| Lymphopenia | 1 | 2014 | 36 | 0.440 |
Why?
|
| Retrospective Studies | 38 | 2024 | 16069 | 0.440 |
Why?
|
| Echocardiography | 8 | 2024 | 1049 | 0.440 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 12 | 0.440 |
Why?
|
| Sensitivity and Specificity | 17 | 2021 | 2019 | 0.440 |
Why?
|
| P-Selectin | 8 | 2010 | 77 | 0.440 |
Why?
|
| Surveys and Questionnaires | 10 | 2022 | 3677 | 0.430 |
Why?
|
| Adolescent | 29 | 2024 | 19127 | 0.430 |
Why?
|
| Brain Infarction | 1 | 2013 | 30 | 0.420 |
Why?
|
| Cell Movement | 6 | 2017 | 831 | 0.420 |
Why?
|
| Leukocytes | 3 | 2014 | 206 | 0.420 |
Why?
|
| Macrophages | 7 | 2024 | 604 | 0.420 |
Why?
|
| Asymptomatic Diseases | 7 | 2020 | 78 | 0.420 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 54 | 0.410 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2024 | 233 | 0.410 |
Why?
|
| Ultrasonography | 13 | 2017 | 942 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 1006 | 0.400 |
Why?
|
| Diet, High-Fat | 6 | 2025 | 212 | 0.400 |
Why?
|
| Flushing | 3 | 2010 | 5 | 0.400 |
Why?
|
| Arteriosclerosis | 7 | 2004 | 137 | 0.400 |
Why?
|
| Nurse Practitioners | 3 | 2018 | 43 | 0.390 |
Why?
|
| Nutrition Surveys | 7 | 2024 | 290 | 0.390 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 280 | 0.390 |
Why?
|
| DNA Fingerprinting | 1 | 2012 | 107 | 0.390 |
Why?
|
| CD11 Antigens | 3 | 2017 | 12 | 0.390 |
Why?
|
| Heart Valves | 2 | 2010 | 51 | 0.390 |
Why?
|
| Administration, Oral | 3 | 2024 | 671 | 0.390 |
Why?
|
| Physician Assistants | 3 | 2018 | 61 | 0.380 |
Why?
|
| CD11b Antigen | 3 | 2009 | 37 | 0.380 |
Why?
|
| DNA | 5 | 2013 | 1594 | 0.380 |
Why?
|
| Integrin alpha Chains | 2 | 2017 | 15 | 0.380 |
Why?
|
| Hyperglycemia | 4 | 2021 | 222 | 0.370 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 114 | 0.370 |
Why?
|
| Coronary Stenosis | 2 | 2011 | 71 | 0.370 |
Why?
|
| Multivariate Analysis | 12 | 2021 | 1414 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 57 | 0.370 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 684 | 0.360 |
Why?
|
| Proteomics | 3 | 2024 | 479 | 0.360 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 1340 | 0.360 |
Why?
|
| Gene Frequency | 8 | 2017 | 716 | 0.360 |
Why?
|
| Postoperative Complications | 10 | 2013 | 3020 | 0.360 |
Why?
|
| Intermittent Claudication | 4 | 2023 | 57 | 0.360 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2023 | 74 | 0.350 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2010 | 1099 | 0.350 |
Why?
|
| Europe | 8 | 2018 | 349 | 0.350 |
Why?
|
| Precision Medicine | 2 | 2024 | 308 | 0.350 |
Why?
|
| Lovastatin | 7 | 2010 | 27 | 0.350 |
Why?
|
| Survival Rate | 12 | 2024 | 2002 | 0.350 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2021 | 31 | 0.340 |
Why?
|
| RNA, Messenger | 20 | 2017 | 2816 | 0.340 |
Why?
|
| Reproducibility of Results | 16 | 2022 | 2844 | 0.340 |
Why?
|
| Stroke Volume | 6 | 2024 | 446 | 0.340 |
Why?
|
| Preoperative Care | 3 | 2012 | 348 | 0.330 |
Why?
|
| Alleles | 10 | 2024 | 1602 | 0.330 |
Why?
|
| Interleukin-1beta | 3 | 2022 | 158 | 0.330 |
Why?
|
| Particle Size | 5 | 2024 | 115 | 0.330 |
Why?
|
| Diet | 7 | 2013 | 1136 | 0.330 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2010 | 37 | 0.330 |
Why?
|
| Femoral Artery | 4 | 2023 | 192 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 502 | 0.330 |
Why?
|
| Health Status Disparities | 3 | 2024 | 221 | 0.320 |
Why?
|
| Pharmacogenetics | 5 | 2024 | 183 | 0.320 |
Why?
|
| Testosterone | 3 | 2024 | 532 | 0.320 |
Why?
|
| E-Selectin | 6 | 2009 | 42 | 0.320 |
Why?
|
| Forecasting | 3 | 2021 | 354 | 0.320 |
Why?
|
| Acute Disease | 5 | 2024 | 1093 | 0.320 |
Why?
|
| Delayed-Action Preparations | 8 | 2010 | 110 | 0.310 |
Why?
|
| Lipase | 6 | 2014 | 88 | 0.310 |
Why?
|
| Platelet Activation | 4 | 2017 | 70 | 0.310 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 226 | 0.310 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2021 | 323 | 0.310 |
Why?
|
| Health Surveys | 3 | 2008 | 243 | 0.300 |
Why?
|
| Cholestyramine Resin | 2 | 2004 | 13 | 0.300 |
Why?
|
| Liver | 14 | 2024 | 1743 | 0.300 |
Why?
|
| Th1 Cells | 3 | 2021 | 152 | 0.300 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 27 | 0.300 |
Why?
|
| Quinazolines | 3 | 2016 | 176 | 0.290 |
Why?
|
| Sex Characteristics | 4 | 2022 | 314 | 0.290 |
Why?
|
| Injections, Subcutaneous | 5 | 2024 | 126 | 0.290 |
Why?
|
| Lipid Regulating Agents | 3 | 2022 | 6 | 0.290 |
Why?
|
| Menopause | 1 | 2008 | 75 | 0.290 |
Why?
|
| Diet Therapy | 2 | 2021 | 42 | 0.290 |
Why?
|
| Ambulatory Care | 4 | 2018 | 378 | 0.290 |
Why?
|
| Cells, Cultured | 15 | 2021 | 3046 | 0.290 |
Why?
|
| Women's Health | 2 | 2020 | 132 | 0.290 |
Why?
|
| Ventricular Remodeling | 2 | 2006 | 174 | 0.280 |
Why?
|
| Professional Practice Gaps | 2 | 2018 | 15 | 0.280 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2015 | 203 | 0.280 |
Why?
|
| Drug Monitoring | 5 | 2021 | 157 | 0.280 |
Why?
|
| Albuminuria | 5 | 2022 | 92 | 0.280 |
Why?
|
| Dendritic Cells | 2 | 2021 | 402 | 0.280 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2025 | 75 | 0.280 |
Why?
|
| Angina, Unstable | 4 | 2021 | 52 | 0.280 |
Why?
|
| CD36 Antigens | 4 | 2022 | 35 | 0.280 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 280 | 0.270 |
Why?
|
| Haplotypes | 6 | 2012 | 517 | 0.270 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 586 | 0.270 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 39 | 0.270 |
Why?
|
| Creatine Kinase | 3 | 2019 | 54 | 0.270 |
Why?
|
| Heart Ventricles | 4 | 2021 | 763 | 0.270 |
Why?
|
| Cognition | 3 | 2024 | 737 | 0.270 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 2013 | 61 | 0.270 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 186 | 0.270 |
Why?
|
| Education, Medical, Continuing | 3 | 2016 | 138 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2007 | 127 | 0.260 |
Why?
|
| Postmenopause | 3 | 2021 | 125 | 0.260 |
Why?
|
| Case-Control Studies | 12 | 2019 | 3239 | 0.260 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1013 | 0.260 |
Why?
|
| Heart | 5 | 2016 | 723 | 0.260 |
Why?
|
| Cystatin C | 4 | 2016 | 49 | 0.260 |
Why?
|
| Body Weight | 2 | 2009 | 1007 | 0.260 |
Why?
|
| Aging | 5 | 2022 | 1185 | 0.260 |
Why?
|
| Chemokines, CC | 1 | 2005 | 28 | 0.260 |
Why?
|
| United Kingdom | 2 | 2024 | 190 | 0.260 |
Why?
|
| Mutation | 11 | 2023 | 5767 | 0.250 |
Why?
|
| Lower Extremity | 3 | 2022 | 183 | 0.250 |
Why?
|
| Social Class | 2 | 2017 | 190 | 0.250 |
Why?
|
| Medical Laboratory Science | 1 | 2005 | 13 | 0.250 |
Why?
|
| Mass Screening | 5 | 2024 | 787 | 0.250 |
Why?
|
| Disease Models, Animal | 11 | 2019 | 4298 | 0.250 |
Why?
|
| Glucose Intolerance | 3 | 2021 | 77 | 0.250 |
Why?
|
| Drug Combinations | 6 | 2019 | 268 | 0.250 |
Why?
|
| Biological Transport | 3 | 2024 | 346 | 0.250 |
Why?
|
| ROC Curve | 4 | 2012 | 558 | 0.240 |
Why?
|
| Interleukin-18 | 2 | 2023 | 60 | 0.240 |
Why?
|
| Heart Valve Diseases | 2 | 2022 | 166 | 0.240 |
Why?
|
| Signal Transduction | 5 | 2021 | 4501 | 0.240 |
Why?
|
| Flow Cytometry | 10 | 2020 | 804 | 0.240 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2010 | 168 | 0.240 |
Why?
|
| Nonprescription Drugs | 2 | 2024 | 46 | 0.240 |
Why?
|
| Confidence Intervals | 5 | 2017 | 279 | 0.240 |
Why?
|
| Allylamine | 1 | 2004 | 7 | 0.240 |
Why?
|
| 3T3-L1 Cells | 2 | 2015 | 56 | 0.240 |
Why?
|
| Internet | 2 | 2024 | 378 | 0.240 |
Why?
|
| Benzodiazepines | 2 | 2017 | 101 | 0.240 |
Why?
|
| Inpatients | 1 | 2009 | 494 | 0.240 |
Why?
|
| Protective Factors | 3 | 2021 | 84 | 0.230 |
Why?
|
| Glucose | 2 | 2021 | 880 | 0.230 |
Why?
|
| Muscles | 3 | 2016 | 288 | 0.230 |
Why?
|
| Blood Platelets | 4 | 2016 | 328 | 0.230 |
Why?
|
| Superantigens | 1 | 2004 | 20 | 0.230 |
Why?
|
| Global Burden of Disease | 1 | 2024 | 25 | 0.230 |
Why?
|
| Insulin | 7 | 2021 | 1208 | 0.230 |
Why?
|
| Apolipoprotein A-V | 3 | 2013 | 20 | 0.230 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 291 | 0.230 |
Why?
|
| Recurrence | 5 | 2019 | 1418 | 0.230 |
Why?
|
| Thiophenes | 2 | 2014 | 60 | 0.230 |
Why?
|
| Immunosuppressive Agents | 6 | 2003 | 644 | 0.230 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2024 | 51 | 0.230 |
Why?
|
| Gemfibrozil | 1 | 2003 | 3 | 0.220 |
Why?
|
| Leukocyte Count | 6 | 2017 | 247 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 1 | 2025 | 353 | 0.220 |
Why?
|
| Databases, Factual | 6 | 2024 | 1171 | 0.220 |
Why?
|
| Prescription Drugs | 2 | 2014 | 52 | 0.220 |
Why?
|
| Myocardial Reperfusion | 5 | 2000 | 73 | 0.220 |
Why?
|
| Listeriosis | 1 | 2003 | 19 | 0.220 |
Why?
|
| Clinical Competence | 4 | 2019 | 972 | 0.220 |
Why?
|
| Fibrosis | 6 | 2022 | 429 | 0.220 |
Why?
|
| Docosahexaenoic Acids | 2 | 2022 | 66 | 0.220 |
Why?
|
| Quality of Health Care | 3 | 2016 | 389 | 0.220 |
Why?
|
| Cardiologists | 1 | 2023 | 19 | 0.220 |
Why?
|
| Adipose Tissue, White | 1 | 2024 | 79 | 0.220 |
Why?
|
| Apoptosis | 5 | 2015 | 1787 | 0.220 |
Why?
|
| Amino Acids | 3 | 2018 | 663 | 0.220 |
Why?
|
| Primary Health Care | 5 | 2018 | 754 | 0.220 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 858 | 0.220 |
Why?
|
| Fishes | 1 | 2023 | 41 | 0.210 |
Why?
|
| Program Evaluation | 1 | 2005 | 448 | 0.210 |
Why?
|
| Cholesterol, VLDL | 4 | 2016 | 15 | 0.210 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 94 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2013 | 667 | 0.210 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 87 | 0.210 |
Why?
|
| Endpoint Determination | 2 | 2021 | 53 | 0.210 |
Why?
|
| Receptor for Advanced Glycation End Products | 4 | 2015 | 25 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 4 | 2014 | 866 | 0.210 |
Why?
|
| Thrombosis | 2 | 2016 | 518 | 0.210 |
Why?
|
| Electrocardiography | 9 | 2021 | 958 | 0.210 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 130 | 0.210 |
Why?
|
| Kidney | 3 | 2022 | 1343 | 0.210 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2019 | 34 | 0.210 |
Why?
|
| Carrier Proteins | 3 | 2021 | 1022 | 0.210 |
Why?
|
| Piperazines | 2 | 2014 | 229 | 0.210 |
Why?
|
| Energy Intake | 2 | 2010 | 490 | 0.210 |
Why?
|
| Aortic Diseases | 2 | 2015 | 198 | 0.210 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 281 | 0.210 |
Why?
|
| Diet, Western | 2 | 2019 | 17 | 0.200 |
Why?
|
| Ultrasonography, Doppler | 3 | 2014 | 197 | 0.200 |
Why?
|
| Albumins | 1 | 2022 | 88 | 0.200 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.200 |
Why?
|
| Hypotension | 1 | 2024 | 177 | 0.200 |
Why?
|
| Circadian Rhythm | 1 | 2024 | 269 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 3 | 2018 | 118 | 0.200 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 449 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 810 | 0.190 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2021 | 4 | 0.190 |
Why?
|
| Spleen | 2 | 2018 | 272 | 0.190 |
Why?
|
| Waist Circumference | 4 | 2014 | 88 | 0.190 |
Why?
|
| Thigh | 3 | 2022 | 50 | 0.190 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 24 | 0.190 |
Why?
|
| Self Medication | 1 | 2021 | 23 | 0.190 |
Why?
|
| Antigens, CD | 5 | 2002 | 420 | 0.190 |
Why?
|
| Health Status Indicators | 2 | 2015 | 120 | 0.190 |
Why?
|
| Stress, Mechanical | 3 | 2016 | 171 | 0.190 |
Why?
|
| Neutrophil Infiltration | 2 | 2002 | 65 | 0.190 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.190 |
Why?
|
| Osteocalcin | 1 | 2021 | 42 | 0.190 |
Why?
|
| Hematopoiesis | 2 | 2022 | 219 | 0.190 |
Why?
|
| Drug Interactions | 3 | 2011 | 253 | 0.190 |
Why?
|
| Diet, Reducing | 3 | 2009 | 90 | 0.180 |
Why?
|
| Corn Oil | 1 | 2020 | 11 | 0.180 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2017 | 445 | 0.180 |
Why?
|
| Propensity Score | 3 | 2012 | 212 | 0.180 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2022 | 52 | 0.180 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.180 |
Why?
|
| Platelet Aggregation | 3 | 2011 | 120 | 0.180 |
Why?
|
| Canada | 2 | 2018 | 293 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2023 | 170 | 0.180 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 605 | 0.180 |
Why?
|
| Nutrition Policy | 1 | 2021 | 100 | 0.180 |
Why?
|
| Blood Vessels | 2 | 2017 | 104 | 0.180 |
Why?
|
| Aortic Valve | 1 | 2024 | 437 | 0.180 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 45 | 0.180 |
Why?
|
| Budgets | 1 | 2020 | 18 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 2 | 2021 | 577 | 0.180 |
Why?
|
| Cardiovascular System | 1 | 2021 | 101 | 0.180 |
Why?
|
| Homozygote | 5 | 2024 | 532 | 0.180 |
Why?
|
| Adipocytes | 3 | 2024 | 158 | 0.180 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 69 | 0.180 |
Why?
|
| Aorta | 3 | 2017 | 542 | 0.180 |
Why?
|
| Membrane Glycoproteins | 4 | 2008 | 413 | 0.180 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 18 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 95 | 0.170 |
Why?
|
| Receptors, Prostaglandin | 3 | 2010 | 22 | 0.170 |
Why?
|
| Metabolomics | 2 | 2025 | 409 | 0.170 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 760 | 0.170 |
Why?
|
| Reference Values | 5 | 2017 | 701 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 111 | 0.170 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 6 | 0.170 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 134 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 31 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2020 | 55 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2020 | 61 | 0.170 |
Why?
|
| Medical History Taking | 1 | 2020 | 106 | 0.170 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 213 | 0.170 |
Why?
|
| Socioeconomic Factors | 5 | 2024 | 865 | 0.170 |
Why?
|
| Benzaldehydes | 2 | 2011 | 11 | 0.170 |
Why?
|
| Perfusion | 2 | 2023 | 200 | 0.170 |
Why?
|
| Contrast Media | 3 | 2019 | 471 | 0.170 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 64 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 332 | 0.170 |
Why?
|
| Curriculum | 4 | 2019 | 714 | 0.170 |
Why?
|
| Sialic Acids | 1 | 1999 | 19 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 29 | 0.170 |
Why?
|
| Hemorrhage | 2 | 2020 | 458 | 0.170 |
Why?
|
| Preventive Medicine | 1 | 2019 | 22 | 0.170 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 204 | 0.170 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 187 | 0.170 |
Why?
|
| Mississippi | 4 | 2024 | 30 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2000 | 54 | 0.170 |
Why?
|
| Oximes | 2 | 2011 | 48 | 0.170 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 52 | 0.170 |
Why?
|
| Lisinopril | 1 | 2019 | 25 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 19 | 0.160 |
Why?
|
| Amlodipine | 1 | 2019 | 22 | 0.160 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2019 | 288 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 115 | 0.160 |
Why?
|
| Inflammasomes | 1 | 2021 | 150 | 0.160 |
Why?
|
| General Practitioners | 1 | 2019 | 17 | 0.160 |
Why?
|
| Proteins | 2 | 2004 | 1040 | 0.160 |
Why?
|
| Metoprolol | 1 | 2019 | 22 | 0.160 |
Why?
|
| Phospholipases A2 | 2 | 2011 | 35 | 0.160 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2018 | 7 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 149 | 0.160 |
Why?
|
| Models, Economic | 1 | 2019 | 51 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2001 | 274 | 0.160 |
Why?
|
| Anti-Obesity Agents | 2 | 2010 | 42 | 0.160 |
Why?
|
| Interferon-gamma | 3 | 2021 | 502 | 0.160 |
Why?
|
| Biological Products | 1 | 2020 | 113 | 0.160 |
Why?
|
| Carboxylic Acids | 1 | 2018 | 24 | 0.160 |
Why?
|
| Exercise Therapy | 2 | 2013 | 152 | 0.160 |
Why?
|
| Transaminases | 1 | 2018 | 32 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 5 | 2019 | 263 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2021 | 772 | 0.160 |
Why?
|
| Placebo Effect | 3 | 2016 | 24 | 0.160 |
Why?
|
| von Willebrand Factor | 4 | 2017 | 196 | 0.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2013 | 266 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 220 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 210 | 0.150 |
Why?
|
| Fructosamine | 1 | 2018 | 6 | 0.150 |
Why?
|
| Creatinine | 4 | 2014 | 382 | 0.150 |
Why?
|
| CD47 Antigen | 1 | 2018 | 7 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 204 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 69 | 0.150 |
Why?
|
| Research Design | 5 | 2016 | 679 | 0.150 |
Why?
|
| Benchmarking | 1 | 2019 | 132 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 195 | 0.150 |
Why?
|
| Deoxyglucose | 1 | 2018 | 30 | 0.150 |
Why?
|
| Chromosome Deletion | 2 | 2000 | 640 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2013 | 44 | 0.150 |
Why?
|
| Ankle Brachial Index | 3 | 2020 | 40 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 538 | 0.150 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2014 | 41 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 459 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 173 | 0.150 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 107 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 360 | 0.150 |
Why?
|
| Quantitative Trait Loci | 3 | 2017 | 282 | 0.150 |
Why?
|
| Chromosome Aberrations | 2 | 2005 | 620 | 0.150 |
Why?
|
| Fibrinogen | 5 | 2023 | 152 | 0.150 |
Why?
|
| Serum Albumin | 1 | 2018 | 109 | 0.150 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2019 | 105 | 0.150 |
Why?
|
| X-Ray Microtomography | 2 | 2015 | 81 | 0.150 |
Why?
|
| Algorithms | 7 | 2016 | 1598 | 0.150 |
Why?
|
| Health Promotion | 1 | 2021 | 390 | 0.150 |
Why?
|
| Blood Chemical Analysis | 2 | 2015 | 78 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 105 | 0.150 |
Why?
|
| Education | 1 | 2018 | 105 | 0.140 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 89 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 25 | 0.140 |
Why?
|
| Blood Specimen Collection | 2 | 2015 | 47 | 0.140 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 155 | 0.140 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 111 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 364 | 0.140 |
Why?
|
| Receptors, CCR2 | 1 | 2017 | 23 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2019 | 331 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2015 | 135 | 0.140 |
Why?
|
| Phylogeny | 1 | 2019 | 694 | 0.140 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 1385 | 0.140 |
Why?
|
| Tablets | 3 | 2008 | 28 | 0.140 |
Why?
|
| Aldosterone | 1 | 2017 | 59 | 0.140 |
Why?
|
| Fibric Acids | 1 | 2016 | 6 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 186 | 0.140 |
Why?
|
| Gadolinium DTPA | 2 | 2019 | 48 | 0.140 |
Why?
|
| Lipid Droplets | 1 | 2017 | 46 | 0.140 |
Why?
|
| Genetic Counseling | 1 | 2018 | 225 | 0.140 |
Why?
|
| Obesity, Abdominal | 2 | 2015 | 37 | 0.140 |
Why?
|
| PPAR gamma | 1 | 2017 | 91 | 0.140 |
Why?
|
| Cell Line | 5 | 2015 | 2772 | 0.140 |
Why?
|
| Systole | 4 | 2019 | 196 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 309 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2019 | 199 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 164 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 350 | 0.130 |
Why?
|
| Glycosphingolipids | 1 | 2016 | 12 | 0.130 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 35 | 0.130 |
Why?
|
| Patient Admission | 1 | 2017 | 183 | 0.130 |
Why?
|
| Heart Arrest | 2 | 2020 | 342 | 0.130 |
Why?
|
| Alanine Transaminase | 2 | 2014 | 152 | 0.130 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2016 | 40 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 458 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 171 | 0.130 |
Why?
|
| Femoral Vein | 1 | 2016 | 51 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2016 | 17 | 0.130 |
Why?
|
| CD11a Antigen | 2 | 2013 | 10 | 0.130 |
Why?
|
| Sex Distribution | 4 | 2024 | 294 | 0.130 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 2526 | 0.130 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 60 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 215 | 0.130 |
Why?
|
| beta 2-Microglobulin | 2 | 2014 | 32 | 0.130 |
Why?
|
| Lipocalins | 2 | 2014 | 25 | 0.130 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 237 | 0.130 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 11 | 0.130 |
Why?
|
| Inservice Training | 1 | 2016 | 55 | 0.130 |
Why?
|
| Diabetic Foot | 1 | 2018 | 156 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2014 | 56 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 228 | 0.120 |
Why?
|
| Membrane Proteins | 3 | 2014 | 1523 | 0.120 |
Why?
|
| Leptin | 3 | 2007 | 214 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 94 | 0.120 |
Why?
|
| White Matter | 1 | 2017 | 180 | 0.120 |
Why?
|
| Phospholipids | 2 | 2014 | 107 | 0.120 |
Why?
|
| Triazines | 1 | 2015 | 29 | 0.120 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 51 | 0.120 |
Why?
|
| Cell Differentiation | 3 | 2008 | 1916 | 0.120 |
Why?
|
| Immunoassay | 2 | 2005 | 124 | 0.120 |
Why?
|
| Safety | 1 | 2016 | 218 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2016 | 191 | 0.120 |
Why?
|
| Internal Medicine | 2 | 2018 | 148 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 251 | 0.120 |
Why?
|
| Early Diagnosis | 2 | 2016 | 179 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 503 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 79 | 0.120 |
Why?
|
| Gene Expression | 7 | 2013 | 1566 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2021 | 1389 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 131 | 0.120 |
Why?
|
| Blood Donors | 1 | 2014 | 62 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 1687 | 0.120 |
Why?
|
| Subtilisins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 220 | 0.110 |
Why?
|
| Occupations | 1 | 2014 | 21 | 0.110 |
Why?
|
| Osteonectin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 243 | 0.110 |
Why?
|
| Chromosome Mapping | 3 | 2019 | 1082 | 0.110 |
Why?
|
| Athletes | 1 | 2014 | 61 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 60 | 0.110 |
Why?
|
| Sitosterols | 1 | 2013 | 9 | 0.110 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 79 | 0.110 |
Why?
|
| Absorption | 1 | 2013 | 52 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 248 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2014 | 236 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 229 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1681 | 0.110 |
Why?
|
| Genetic Pleiotropy | 1 | 2013 | 24 | 0.110 |
Why?
|
| Panniculitis | 1 | 2013 | 19 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2021 | 442 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 210 | 0.110 |
Why?
|
| Umbilical Veins | 2 | 2006 | 71 | 0.110 |
Why?
|
| Pulse Wave Analysis | 3 | 2021 | 47 | 0.110 |
Why?
|
| Graft Rejection | 5 | 2005 | 587 | 0.110 |
Why?
|
| HEK293 Cells | 3 | 2021 | 738 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 91 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 421 | 0.110 |
Why?
|
| Family Practice | 2 | 2011 | 90 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 85 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 240 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 86 | 0.110 |
Why?
|
| Models, Statistical | 2 | 2013 | 471 | 0.110 |
Why?
|
| Exome | 2 | 2018 | 1040 | 0.110 |
Why?
|
| Internationality | 2 | 2024 | 129 | 0.110 |
Why?
|
| Drug Approval | 1 | 2013 | 40 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 361 | 0.110 |
Why?
|
| Neck | 1 | 2014 | 138 | 0.100 |
Why?
|
| Mice, Obese | 2 | 2013 | 78 | 0.100 |
Why?
|
| Pharmacogenomic Testing | 2 | 2024 | 37 | 0.100 |
Why?
|
| Tangier Disease | 1 | 2012 | 5 | 0.100 |
Why?
|
| Musculoskeletal Diseases | 2 | 2003 | 55 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2013 | 147 | 0.100 |
Why?
|
| Base Sequence | 10 | 2011 | 3091 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 223 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 149 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 577 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 159 | 0.100 |
Why?
|
| Renal Dialysis | 2 | 2010 | 844 | 0.100 |
Why?
|
| Glucose Tolerance Test | 3 | 2021 | 209 | 0.100 |
Why?
|
| Blotting, Northern | 7 | 2003 | 259 | 0.100 |
Why?
|
| Solubility | 3 | 2014 | 132 | 0.100 |
Why?
|
| 3T3 Cells | 3 | 2005 | 129 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 129 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.100 |
Why?
|
| Molecular Sequence Data | 10 | 2011 | 3867 | 0.100 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2022 | 136 | 0.100 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 190 | 0.100 |
Why?
|
| Models, Biological | 3 | 2014 | 1450 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 109 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 311 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8114 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 165 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 313 | 0.100 |
Why?
|
| Age of Onset | 2 | 2025 | 581 | 0.090 |
Why?
|
| Angiopoietin-like Proteins | 2 | 2022 | 12 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2016 | 239 | 0.090 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2011 | 9 | 0.090 |
Why?
|
| Colestipol | 2 | 2004 | 6 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 110 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 125 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2009 | 1584 | 0.090 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 45 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2016 | 233 | 0.090 |
Why?
|
| Polysomnography | 3 | 2019 | 142 | 0.090 |
Why?
|
| Platelet Function Tests | 1 | 2011 | 38 | 0.090 |
Why?
|
| Necrosis | 1 | 2011 | 205 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 967 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 1990 | 140 | 0.090 |
Why?
|
| Brain | 3 | 2017 | 2966 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 524 | 0.090 |
Why?
|
| Diet, Fat-Restricted | 2 | 2011 | 41 | 0.090 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 135 | 0.090 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 26 | 0.090 |
Why?
|
| Vasculitis | 1 | 2011 | 49 | 0.090 |
Why?
|
| Chagas Disease | 1 | 2014 | 287 | 0.090 |
Why?
|
| Fatty Acid Desaturases | 2 | 2025 | 9 | 0.090 |
Why?
|
| Motor Activity | 2 | 2015 | 522 | 0.090 |
Why?
|
| Sirolimus | 2 | 2002 | 220 | 0.090 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 127 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 116 | 0.090 |
Why?
|
| Protein Binding | 4 | 2017 | 1743 | 0.090 |
Why?
|
| Independent Living | 2 | 2024 | 65 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2005 | 209 | 0.090 |
Why?
|
| Health Services Research | 1 | 2011 | 187 | 0.090 |
Why?
|
| Integrins | 2 | 2008 | 82 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 136 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 65 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 64 | 0.080 |
Why?
|
| Aryldialkylphosphatase | 2 | 2007 | 9 | 0.080 |
Why?
|
| Age Distribution | 2 | 2018 | 410 | 0.080 |
Why?
|
| Cyclosporine | 2 | 2003 | 146 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2009 | 62 | 0.080 |
Why?
|
| Cyclosporins | 1 | 1989 | 74 | 0.080 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2014 | 389 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 463 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1239 | 0.080 |
Why?
|
| Tunica Media | 2 | 2010 | 13 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 268 | 0.080 |
Why?
|
| Chemotactic Factors | 2 | 2007 | 17 | 0.080 |
Why?
|
| Diastole | 2 | 2020 | 168 | 0.080 |
Why?
|
| Quinazolinones | 3 | 2016 | 6 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 67 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 594 | 0.080 |
Why?
|
| Chemokines | 1 | 2009 | 136 | 0.080 |
Why?
|
| Antigens, Surface | 1 | 1989 | 121 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1990 | 143 | 0.080 |
Why?
|
| Fasting | 3 | 2013 | 300 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 257 | 0.080 |
Why?
|
| Piperidines | 1 | 2010 | 202 | 0.080 |
Why?
|
| Chymases | 1 | 2008 | 6 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2019 | 1473 | 0.080 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 13 | 0.080 |
Why?
|
| Endocrinology | 1 | 2011 | 141 | 0.080 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 107 | 0.080 |
Why?
|
| Blood Component Removal | 2 | 2000 | 32 | 0.080 |
Why?
|
| Evidence-Based Medicine | 3 | 2015 | 623 | 0.080 |
Why?
|
| RNA Interference | 2 | 2020 | 499 | 0.080 |
Why?
|
| Chronic Disease | 4 | 2024 | 1168 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2012 | 478 | 0.080 |
Why?
|
| Morbidity | 3 | 2014 | 241 | 0.080 |
Why?
|
| Remission Induction | 2 | 2016 | 299 | 0.070 |
Why?
|
| Peritonitis | 3 | 2017 | 76 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2008 | 59 | 0.070 |
Why?
|
| Cloning, Molecular | 5 | 2005 | 892 | 0.070 |
Why?
|
| Apolipoprotein B-100 | 3 | 2016 | 33 | 0.070 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 659 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2010 | 305 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2015 | 676 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2010 | 195 | 0.070 |
Why?
|
| Fibrinolytic Agents | 2 | 2023 | 198 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 141 | 0.070 |
Why?
|
| Alcoholic Beverages | 1 | 2007 | 18 | 0.070 |
Why?
|
| Cadherins | 1 | 2008 | 164 | 0.070 |
Why?
|
| Iceland | 1 | 2007 | 11 | 0.070 |
Why?
|
| Assisted Circulation | 1 | 1987 | 34 | 0.070 |
Why?
|
| Dogs | 9 | 2000 | 764 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 1999 | 151 | 0.070 |
Why?
|
| Drug Utilization | 2 | 2020 | 159 | 0.070 |
Why?
|
| Appetite Depressants | 1 | 2007 | 22 | 0.070 |
Why?
|
| Naphthalenes | 1 | 1987 | 37 | 0.070 |
Why?
|
| Xanthomatosis | 1 | 1987 | 7 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2008 | 187 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2006 | 24 | 0.070 |
Why?
|
| Memory, Episodic | 2 | 2017 | 26 | 0.070 |
Why?
|
| Brain Diseases, Metabolic | 1 | 1987 | 12 | 0.070 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 29 | 0.070 |
Why?
|
| Linkage Disequilibrium | 3 | 2019 | 309 | 0.070 |
Why?
|
| Weight Gain | 3 | 2017 | 400 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 1063 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2022 | 13918 | 0.070 |
Why?
|
| CD3 Complex | 1 | 2007 | 84 | 0.070 |
Why?
|
| Maryland | 2 | 2017 | 28 | 0.070 |
Why?
|
| North Carolina | 2 | 2017 | 58 | 0.070 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 630 | 0.070 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2006 | 28 | 0.070 |
Why?
|
| Exercise Test | 3 | 2020 | 249 | 0.070 |
Why?
|
| Minnesota | 2 | 2017 | 132 | 0.070 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 177 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 158 | 0.070 |
Why?
|
| Health Status | 1 | 2008 | 375 | 0.070 |
Why?
|
| Mice, Mutant Strains | 3 | 1997 | 388 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2018 | 1161 | 0.060 |
Why?
|
| Chemokine CCL11 | 1 | 2005 | 12 | 0.060 |
Why?
|
| Glycation End Products, Advanced | 2 | 2018 | 20 | 0.060 |
Why?
|
| Educational Status | 2 | 2017 | 270 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 87 | 0.060 |
Why?
|
| Restriction Mapping | 3 | 1994 | 188 | 0.060 |
Why?
|
| Fibronectins | 1 | 2005 | 102 | 0.060 |
Why?
|
| Microspheres | 1 | 2005 | 70 | 0.060 |
Why?
|
| Homocysteine | 2 | 2022 | 122 | 0.060 |
Why?
|
| Health Priorities | 1 | 2005 | 36 | 0.060 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2016 | 63 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2058 | 0.060 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2004 | 4 | 0.060 |
Why?
|
| Species Specificity | 1 | 2005 | 550 | 0.060 |
Why?
|
| Ionomycin | 1 | 2004 | 15 | 0.060 |
Why?
|
| Critical Illness | 2 | 2020 | 591 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2004 | 68 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 1997 | 2695 | 0.060 |
Why?
|
| Massachusetts | 1 | 2024 | 124 | 0.060 |
Why?
|
| Walking Speed | 1 | 2024 | 15 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2024 | 25 | 0.060 |
Why?
|
| Endarterectomy, Carotid | 2 | 2015 | 92 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2013 | 1012 | 0.060 |
Why?
|
| Knowledge Bases | 1 | 2024 | 35 | 0.060 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2024 | 12 | 0.060 |
Why?
|
| Enterotoxins | 1 | 2004 | 82 | 0.060 |
Why?
|
| Ezetimibe, Simvastatin Drug Combination | 3 | 2009 | 3 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 240 | 0.060 |
Why?
|
| Teaching | 1 | 2005 | 183 | 0.060 |
Why?
|
| Anthropometry | 2 | 2014 | 198 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2024 | 59 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 260 | 0.060 |
Why?
|
| Listeria monocytogenes | 1 | 2003 | 29 | 0.060 |
Why?
|
| Colony Count, Microbial | 1 | 2003 | 89 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 256 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 98 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2004 | 328 | 0.050 |
Why?
|
| RNA | 2 | 2005 | 570 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 262 | 0.050 |
Why?
|
| Nausea | 1 | 2003 | 97 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2023 | 132 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1013 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 153 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 54 | 0.050 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2002 | 2 | 0.050 |
Why?
|
| Vitamin B Complex | 1 | 2003 | 41 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 59 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2004 | 2586 | 0.050 |
Why?
|
| Length of Stay | 1 | 2009 | 1290 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 197 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2003 | 314 | 0.050 |
Why?
|
| Plasminogen | 2 | 2014 | 7 | 0.050 |
Why?
|
| Body Composition | 1 | 2005 | 516 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 113 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2003 | 61 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2023 | 68 | 0.050 |
Why?
|
| Mineral Oil | 1 | 2022 | 4 | 0.050 |
Why?
|
| Patient Discharge | 2 | 2018 | 492 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2002 | 50 | 0.050 |
Why?
|
| Poloxamer | 1 | 2022 | 12 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2023 | 235 | 0.050 |
Why?
|
| Metabolome | 1 | 2025 | 294 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2024 | 184 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2000 | 172 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 319 | 0.050 |
Why?
|
| Caloric Restriction | 2 | 2013 | 85 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 121 | 0.050 |
Why?
|
| Reperfusion Injury | 2 | 2002 | 103 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2022 | 65 | 0.050 |
Why?
|
| Software Validation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2002 | 46 | 0.050 |
Why?
|
| Child | 5 | 2024 | 24256 | 0.050 |
Why?
|
| Hybrid Cells | 3 | 2008 | 80 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 249 | 0.050 |
Why?
|
| Diarrhea | 1 | 2003 | 315 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2021 | 61 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2001 | 30 | 0.050 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2021 | 78 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 65 | 0.050 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2001 | 41 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 1860 | 0.050 |
Why?
|
| Esterases | 1 | 2001 | 13 | 0.050 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2021 | 95 | 0.050 |
Why?
|
| Meningoencephalitis | 1 | 2001 | 19 | 0.050 |
Why?
|
| Community-Based Participatory Research | 2 | 2013 | 49 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2021 | 103 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 91 | 0.050 |
Why?
|
| Receptors, Leptin | 1 | 2021 | 42 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2012 | 789 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2002 | 296 | 0.050 |
Why?
|
| Proteome | 1 | 2022 | 236 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2021 | 65 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2001 | 154 | 0.050 |
Why?
|
| Capsules | 1 | 2000 | 21 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2020 | 44 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2021 | 68 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 240 | 0.040 |
Why?
|
| Otitis Media | 1 | 2001 | 82 | 0.040 |
Why?
|
| Peroxidase | 1 | 2001 | 62 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2003 | 372 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 383 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1998 | 143 | 0.040 |
Why?
|
| fas Receptor | 1 | 2000 | 41 | 0.040 |
Why?
|
| Chlamydophila Infections | 1 | 2000 | 3 | 0.040 |
Why?
|
| Kinetics | 3 | 2000 | 1318 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2000 | 11 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 63 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 9 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 25 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 239 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2020 | 1102 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2021 | 149 | 0.040 |
Why?
|
| NADPH Dehydrogenase | 1 | 2000 | 7 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2021 | 384 | 0.040 |
Why?
|
| Meningitis, Bacterial | 1 | 2001 | 94 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 58 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2021 | 393 | 0.040 |
Why?
|
| Thymus Gland | 2 | 1991 | 100 | 0.040 |
Why?
|
| Diffusion Chambers, Culture | 1 | 1999 | 6 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 147 | 0.040 |
Why?
|
| Interphase | 1 | 1999 | 45 | 0.040 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 70 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 98 | 0.040 |
Why?
|
| Homeostasis | 1 | 2024 | 683 | 0.040 |
Why?
|
| Sialyltransferases | 1 | 1999 | 6 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 89 | 0.040 |
Why?
|
| Carbohydrate Conformation | 1 | 1999 | 16 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 105 | 0.040 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 615 | 0.040 |
Why?
|
| Rheology | 1 | 1999 | 31 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2014 | 833 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 143 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 58 | 0.040 |
Why?
|
| Lectins | 1 | 1999 | 50 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 7 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2000 | 113 | 0.040 |
Why?
|
| Ureteral Obstruction | 1 | 2000 | 105 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 300 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 1999 | 2 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 103 | 0.040 |
Why?
|
| Family | 1 | 2022 | 567 | 0.040 |
Why?
|
| Overweight | 2 | 2015 | 358 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 264 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 940 | 0.040 |
Why?
|
| Exons | 3 | 2014 | 794 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 173 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 280 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 172 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 43 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 169 | 0.040 |
Why?
|
| Certification | 1 | 2019 | 67 | 0.040 |
Why?
|
| Placebos | 2 | 2011 | 241 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 220 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2316 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 999 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 170 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 29 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2001 | 372 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 488 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2017 | 423 | 0.040 |
Why?
|
| Talin | 1 | 2018 | 8 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 1987 | 1026 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 2018 | 33 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 232 | 0.040 |
Why?
|
| Poverty | 1 | 2022 | 418 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 376 | 0.040 |
Why?
|
| Microcirculation | 1 | 1998 | 93 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 269 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 83 | 0.040 |
Why?
|
| Health Facilities | 1 | 2018 | 58 | 0.040 |
Why?
|
| ATP Binding Cassette Transporter 1 | 2 | 2012 | 16 | 0.040 |
Why?
|
| Immunoturbidimetry | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 243 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 1754 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2000 | 303 | 0.040 |
Why?
|
| Interleukin-12 | 2 | 2013 | 113 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 304 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2000 | 400 | 0.040 |
Why?
|
| Phagocytes | 1 | 1997 | 24 | 0.040 |
Why?
|
| Preliminary Data | 1 | 2017 | 7 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.040 |
Why?
|
| Sequestering Agents | 1 | 2017 | 2 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 381 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1289 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2002 | 679 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2019 | 197 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 46 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 157 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 367 | 0.040 |
Why?
|
| Mammography | 1 | 2018 | 113 | 0.040 |
Why?
|
| Genome, Human | 2 | 2017 | 1265 | 0.040 |
Why?
|
| England | 1 | 2017 | 57 | 0.040 |
Why?
|
| Factor VIII | 1 | 2017 | 44 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 527 | 0.040 |
Why?
|
| Quebec | 1 | 2017 | 5 | 0.040 |
Why?
|
| Thioglycolates | 1 | 1997 | 6 | 0.040 |
Why?
|
| Vitamin E | 1 | 2017 | 65 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 57 | 0.040 |
Why?
|
| Acyl Coenzyme A | 1 | 1997 | 24 | 0.030 |
Why?
|
| France | 1 | 2017 | 78 | 0.030 |
Why?
|
| Bacteremia | 1 | 2001 | 405 | 0.030 |
Why?
|
| Income | 1 | 2017 | 133 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 335 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 1997 | 29 | 0.030 |
Why?
|
| Radiography | 2 | 2017 | 822 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 543 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2000 | 483 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1997 | 209 | 0.030 |
Why?
|
| Adipokines | 1 | 2017 | 58 | 0.030 |
Why?
|
| Phosphorus | 1 | 2017 | 56 | 0.030 |
Why?
|
| Platelet Count | 1 | 2017 | 135 | 0.030 |
Why?
|
| Magnesium | 1 | 2017 | 121 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2000 | 402 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 24 | 0.030 |
Why?
|
| Probability | 2 | 2010 | 321 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 79 | 0.030 |
Why?
|
| Endocytosis | 1 | 2017 | 123 | 0.030 |
Why?
|
| Binding Sites | 1 | 1999 | 1294 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1997 | 99 | 0.030 |
Why?
|
| Adenoviridae | 1 | 1999 | 604 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 514 | 0.030 |
Why?
|
| Myalgia | 1 | 2016 | 11 | 0.030 |
Why?
|
| Cricetulus | 1 | 2016 | 97 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 1703 | 0.030 |
Why?
|
| CHO Cells | 1 | 2016 | 157 | 0.030 |
Why?
|
| Hyperemia | 1 | 2016 | 25 | 0.030 |
Why?
|
| Corrosion Casting | 1 | 1995 | 3 | 0.030 |
Why?
|
| Blood Volume | 1 | 2016 | 80 | 0.030 |
Why?
|
| C-Peptide | 1 | 2016 | 113 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 48 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 1995 | 15 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2017 | 90 | 0.030 |
Why?
|
| California | 1 | 2016 | 127 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 36 | 0.030 |
Why?
|
| Introns | 1 | 2017 | 301 | 0.030 |
Why?
|
| Knee Joint | 1 | 2017 | 160 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 397 | 0.030 |
Why?
|
| Death Certificates | 1 | 2015 | 9 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 425 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 202 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 238 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 60 | 0.030 |
Why?
|
| Receptors, Very Late Antigen | 1 | 1995 | 5 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2018 | 299 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 1995 | 30 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 289 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 1999 | 939 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1995 | 77 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 2015 | 46 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2016 | 206 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 20 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 926 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2017 | 303 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 312 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2013 | 796 | 0.030 |
Why?
|
| DNA Probes | 2 | 1995 | 123 | 0.030 |
Why?
|
| Vitamin B 6 | 2 | 2006 | 10 | 0.030 |
Why?
|
| Myocarditis | 2 | 1994 | 119 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 482 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 270 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 88 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 347 | 0.030 |
Why?
|
| Phospholipases | 1 | 1994 | 7 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 132 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 234 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 29 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 327 | 0.030 |
Why?
|
| Lymph | 3 | 2000 | 25 | 0.030 |
Why?
|
| Radionuclide Imaging | 3 | 1991 | 151 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2014 | 55 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 69 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 35 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 30 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 143 | 0.030 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2014 | 22 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 275 | 0.030 |
Why?
|
| Genetic Code | 1 | 2014 | 40 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1100 | 0.030 |
Why?
|
| Proinsulin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 111 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 251 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 229 | 0.030 |
Why?
|
| Dermatitis, Contact | 1 | 1993 | 7 | 0.030 |
Why?
|
| Cricetinae | 2 | 2005 | 410 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 231 | 0.030 |
Why?
|
| Cattle | 2 | 2006 | 562 | 0.030 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 7 | 0.030 |
Why?
|
| Random Allocation | 2 | 1996 | 433 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 100 | 0.030 |
Why?
|
| Rats | 2 | 2002 | 3666 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2012 | 30 | 0.030 |
Why?
|
| Endosonography | 1 | 2013 | 84 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 539 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 154 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1992 | 31 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 1993 | 148 | 0.030 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 57 | 0.030 |
Why?
|
| Reoperation | 1 | 1996 | 819 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1992 | 162 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 517 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 413 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 55 | 0.020 |
Why?
|
| Stem Cells | 1 | 1997 | 702 | 0.020 |
Why?
|
| Corneal Stroma | 1 | 2012 | 90 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 18 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 580 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 59 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 126 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 48 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 201 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2015 | 546 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 35 | 0.020 |
Why?
|
| Autoradiography | 1 | 1991 | 71 | 0.020 |
Why?
|
| DNA Primers | 2 | 2007 | 660 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 1991 | 56 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 215 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 1991 | 162 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2013 | 255 | 0.020 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2010 | 15 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2011 | 91 | 0.020 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2010 | 7 | 0.020 |
Why?
|
| Neoplasms | 2 | 2017 | 2758 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 284 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2398 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2010 | 50 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 304 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 396 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2012 | 239 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2011 | 121 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 255 | 0.020 |
Why?
|
| Integrin alpha4 | 2 | 2002 | 9 | 0.020 |
Why?
|
| Oxygen | 1 | 1993 | 550 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 92 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 93 | 0.020 |
Why?
|
| Markov Chains | 1 | 2010 | 83 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 178 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2009 | 35 | 0.020 |
Why?
|
| Pregnancy | 2 | 2013 | 7129 | 0.020 |
Why?
|
| Adiposity | 1 | 2011 | 191 | 0.020 |
Why?
|
| Gestational Age | 1 | 2013 | 1137 | 0.020 |
Why?
|
| Antibodies, Blocking | 2 | 2002 | 61 | 0.020 |
Why?
|
| Metabolic Equivalent | 1 | 2009 | 6 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2011 | 161 | 0.020 |
Why?
|
| In Situ Hybridization | 3 | 1995 | 472 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 397 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2009 | 112 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 325 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 1474 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1577 | 0.020 |
Why?
|
| Lung | 2 | 1993 | 1465 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2010 | 164 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2002 | 555 | 0.020 |
Why?
|
| Sports | 1 | 2009 | 59 | 0.020 |
Why?
|
| Interleukin-4 | 2 | 2000 | 138 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 231 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1990 | 452 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 6 | 0.020 |
Why?
|
| Leishmania major | 1 | 2008 | 24 | 0.020 |
Why?
|
| Complement Factor H | 1 | 2008 | 19 | 0.020 |
Why?
|
| Epinephrine | 1 | 2009 | 175 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1988 | 120 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 54 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1663 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 476 | 0.020 |
Why?
|
| Collagen | 1 | 2009 | 317 | 0.020 |
Why?
|
| Caspase 10 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1989 | 145 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 101 | 0.020 |
Why?
|
| Chenodeoxycholic Acid | 1 | 1987 | 14 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 53 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1987 | 142 | 0.020 |
Why?
|
| Tendons | 1 | 1987 | 41 | 0.020 |
Why?
|
| Angiography | 1 | 1987 | 215 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2008 | 204 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 469 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1987 | 333 | 0.020 |
Why?
|
| Allergens | 1 | 2008 | 249 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2008 | 182 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1525 | 0.020 |
Why?
|
| Umbilical Cord | 1 | 2005 | 55 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 254 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 382 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 463 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2005 | 251 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2008 | 378 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2005 | 136 | 0.010 |
Why?
|
| Stents | 1 | 2011 | 876 | 0.010 |
Why?
|
| Epitopes | 1 | 2005 | 430 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1995 | 657 | 0.010 |
Why?
|
| Pyridoxal Phosphate | 1 | 2003 | 14 | 0.010 |
Why?
|
| Hemostasis | 1 | 2003 | 68 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2004 | 166 | 0.010 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 2003 | 13 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2005 | 348 | 0.010 |
Why?
|
| Ion Transport | 1 | 2003 | 49 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 2003 | 41 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 135 | 0.010 |
Why?
|
| Causality | 1 | 2003 | 83 | 0.010 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2002 | 27 | 0.010 |
Why?
|
| Integrin alphaXbeta2 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2002 | 16 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 2002 | 17 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 178 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2003 | 191 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 339 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2002 | 101 | 0.010 |
Why?
|
| Lipopolysaccharides | 2 | 1993 | 293 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 287 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 901 | 0.010 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2000 | 3 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2000 | 5 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2000 | 8 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2006 | 707 | 0.010 |
Why?
|
| Coenzyme A Ligases | 1 | 2000 | 6 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 23 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 21 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 292 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2000 | 54 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2000 | 33 | 0.010 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2000 | 19 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2000 | 82 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 80 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 75 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2000 | 96 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1993 | 447 | 0.010 |
Why?
|
| Ligation | 1 | 2000 | 134 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 51 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 162 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2000 | 151 | 0.010 |
Why?
|
| Azepines | 1 | 2000 | 61 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 2000 | 114 | 0.010 |
Why?
|
| Food-Drug Interactions | 1 | 1999 | 10 | 0.010 |
Why?
|
| Triazoles | 1 | 2000 | 138 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1998 | 22 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1998 | 48 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2000 | 150 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1998 | 36 | 0.010 |
Why?
|
| Osteopontin | 1 | 1998 | 49 | 0.010 |
Why?
|
| Mast Cells | 1 | 1998 | 74 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 424 | 0.010 |
Why?
|
| Histamine Release | 1 | 1997 | 10 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2000 | 529 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1996 | 43 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1997 | 75 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1996 | 34 | 0.010 |
Why?
|
| Veins | 1 | 1997 | 106 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1996 | 284 | 0.010 |
Why?
|
| Complement C5a | 1 | 1995 | 23 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 879 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1999 | 843 | 0.010 |
Why?
|
| Transfection | 1 | 1996 | 1068 | 0.010 |
Why?
|
| Software | 1 | 1999 | 675 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1993 | 39 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1993 | 99 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1993 | 147 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1994 | 623 | 0.010 |
Why?
|
| Genes | 1 | 1993 | 444 | 0.010 |
Why?
|
| Death | 1 | 1993 | 70 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 287 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1993 | 243 | 0.010 |
Why?
|
| Gene Library | 1 | 1992 | 220 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 14 | 0.010 |
Why?
|
| Swine | 1 | 1994 | 1167 | 0.010 |
Why?
|